The Competition Commission of India has approved the proposed combination involving (i) demerger of the identified business undertaking of AHEL into AHTL; (ii) Merger and amalgamation of AHL and Keimed with and into AHTL; and (iii) acquisition of 74.5% shareholding of AMPL by AHTL.

The proposed combination involves the following:

1. Step 1: demerger of the identified business undertaking of Apollo Health Enterprise Limited (AHEL) (Identified Business Undertaking Demerger) into Apollo Healthtech Limited (AHTL), in accordance with a composite scheme of arrangement approved by the boards of directors and audit committees of Apollo Healthco Limited (AHL) and Keimed Private Limited (Keimed) on 27^th June 2025, and AHEL and AHTL on 30^th June 2025 (Composite Scheme);
2. Step 2: merger and amalgamation of AHL with and into AHTL (AHL Merger) in accordance with the Composite Scheme;
3. Step 3: merger and amalgamation of Keimed with and into AHTL(Keimed Merger) in accordance with the Composite Scheme;
4. Step 4: listing of the equity shares of AHTL on the stock exchanges, subsequent to effectiveness of the Composite Scheme; and 
5. Step 5: Acquisition of 74.5% shareholding of AMPL from existing shareholders by AHTL (AMPL Acquisition) in accordance with the applicable regulatory framework and in terms of a Share Purchase Agreement (SPA) executed between AHL, AMPL and the existing shareholders of AMPL (AMPL SPA).

AHTL is a newly incorporated company and currently does not have any activities worldwide or in India.

AHL operates the “Apollo 24|7” platform which helps users/customers to book doctor appointments and diagnostic tests. AHL also operates in the pharmacy distribution segment.

Keimed is involved in the business of: (i) wholesale sale and distribution of pharmaceutical products, OTC products, medical equipment, surgical products, scientific apparatus and equipment for hospitals and FMCG; (ii) retail sale of specialty pharmaceutical products through certain subsidiaries and (iii) marketing and sale of pharmaceutical products.

Detailed order of the Commission will follow.

*****

NB/AD

(Release ID: 2170267) Visitor Counter : 64